- Home
- PMX vs CATX Comparison
PMX vs CATX Comparison
Compare PMX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- CATX
- Stock Information
- Founded
- PMX 2002
- CATX 1983
- Country
- PMX United States
- CATX United States
- Employees
- PMX N/A
- CATX N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- CATX Medical/Dental Instruments
- Sector
- PMX Finance
- CATX Health Care
- Exchange
- PMX Nasdaq
- CATX Nasdaq
- Market Cap
- PMX 219.7M
- CATX 239.0M
- IPO Year
- PMX N/A
- CATX N/A
- Fundamental
- Price
- PMX $6.68
- CATX $3.87
- Analyst Decision
- PMX
- CATX Strong Buy
- Analyst Count
- PMX 0
- CATX 11
- Target Price
- PMX N/A
- CATX $12.90
- AVG Volume (30 Days)
- PMX 101.5K
- CATX 884.5K
- Earning Date
- PMX 01-01-0001
- CATX 08-13-2025
- Dividend Yield
- PMX 5.28%
- CATX N/A
- EPS Growth
- PMX N/A
- CATX N/A
- EPS
- PMX N/A
- CATX N/A
- Revenue
- PMX N/A
- CATX $1,471,000.00
- Revenue This Year
- PMX N/A
- CATX N/A
- Revenue Next Year
- PMX N/A
- CATX $11.99
- P/E Ratio
- PMX N/A
- CATX N/A
- Revenue Growth
- PMX N/A
- CATX N/A
- 52 Week Low
- PMX $6.09
- CATX $1.60
- 52 Week High
- PMX $8.47
- CATX $16.55
- Technical
- Relative Strength Index (RSI)
- PMX 74.33
- CATX 52.16
- Support Level
- PMX $6.50
- CATX $3.88
- Resistance Level
- PMX $6.69
- CATX $4.28
- Average True Range (ATR)
- PMX 0.06
- CATX 0.24
- MACD
- PMX 0.03
- CATX -0.07
- Stochastic Oscillator
- PMX 100.00
- CATX 27.27
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.